Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063829 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients
A Phase 2 study, sponsored by AiCuris Anti-infective Cures.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT01063829: Completed Phase 2 study, sponsored by AiCuris Anti-infective Cures.
NCT01063829 is a Phase 2 study that has completed, run by AiCuris Anti-infective Cures. The registered enrollment target is 133 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01063829, a Phase 2 study, has completed, sponsored by AiCuris Anti-infective Cures.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).
Interventions
- OTHER Placebo
- DRUG 60 mg AIC246
- DRUG 120 mg AIC246
- DRUG 240 mg AIC246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01063829 record still lists
NCT01063829 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01063829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01063829 about?
NCT01063829 is a clinical study titled "Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients". The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).
What is the current status of trial NCT01063829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2010-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01063829?
The interventions under investigation include: Placebo (OTHER), 60 mg AIC246 (DRUG), 120 mg AIC246 (DRUG), 240 mg AIC246 (DRUG).
Who is sponsoring clinical trial NCT01063829?
This trial is sponsored by AiCuris Anti-infective Cures, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01063829's enrollment target sits among peer trials
133 538th of 2000 higher than 1,462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia